
NextPoint Therapeutics Announces Clinical Debut of Novel NPX372 for Solid Tumor Treatment
NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors NextPoint Therapeutics, a clinical-stage biotechnology company developing a new world of precision therapeutics…












